JP2004505912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004505912A5 JP2004505912A5 JP2002517052A JP2002517052A JP2004505912A5 JP 2004505912 A5 JP2004505912 A5 JP 2004505912A5 JP 2002517052 A JP2002517052 A JP 2002517052A JP 2002517052 A JP2002517052 A JP 2002517052A JP 2004505912 A5 JP2004505912 A5 JP 2004505912A5
- Authority
- JP
- Japan
- Prior art keywords
- guanidine
- nitrobenzylideneamino
- composition according
- guanidine acetate
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 22
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 6
- 208000022531 anorexia Diseases 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004378 Melanocortin Receptors Human genes 0.000 description 2
- 108090000950 Melanocortin Receptors Proteins 0.000 description 2
- 108010008364 Melanocortins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002865 melanocortin Substances 0.000 description 2
- -1 methoxy, hydroxy Chemical group 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- UEYMVLYFTKJDHE-UHFFFAOYSA-N 2-[(2,3,4-trimethoxyphenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.COC1=CC=C(C=NNC(N)=N)C(OC)=C1OC UEYMVLYFTKJDHE-UHFFFAOYSA-N 0.000 description 1
- WHSMHQQGLVVQJZ-UHFFFAOYSA-N 2-[(2,3-dimethoxy-5-nitrophenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.COC1=CC([N+]([O-])=O)=CC(C=NNC(N)=N)=C1OC WHSMHQQGLVVQJZ-UHFFFAOYSA-N 0.000 description 1
- HDLADIYRGZTSTC-UHFFFAOYSA-N 2-[(2-hydroxy-4-methoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound COC1=CC(O)=C(C=NNC(N)=N)C=C1[N+]([O-])=O HDLADIYRGZTSTC-UHFFFAOYSA-N 0.000 description 1
- ZPPQPYVAWOBQSX-UHFFFAOYSA-N 2-[(3-bromo-2,6-dinitrophenyl)methylideneamino]guanidine hydrochloride Chemical compound Cl.NC(=N)NN=CC1=C([N+]([O-])=O)C=CC(Br)=C1[N+]([O-])=O ZPPQPYVAWOBQSX-UHFFFAOYSA-N 0.000 description 1
- QZPYZNYEFBAJQK-UHFFFAOYSA-N 2-[(3-chloro-4-methoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound COC1=C(Cl)C=C(C=NNC(N)=N)C=C1[N+]([O-])=O QZPYZNYEFBAJQK-UHFFFAOYSA-N 0.000 description 1
- FBQIPMYAOJAAAR-UHFFFAOYSA-N 2-[(3-iodophenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.NC(=N)NN=CC1=CC=CC(I)=C1 FBQIPMYAOJAAAR-UHFFFAOYSA-N 0.000 description 1
- UTPLZJPUVNVQNQ-UHFFFAOYSA-N 2-[(5-bromo-2-hydroxy-3-nitrophenyl)methylideneamino]guanidine hydrochloride Chemical compound Cl.NC(=N)NN=CC1=CC(Br)=CC([N+]([O-])=O)=C1O UTPLZJPUVNVQNQ-UHFFFAOYSA-N 0.000 description 1
- WSNKYMRJFVHMND-UHFFFAOYSA-N 2-[(5-bromo-2-methoxy-3-nitrophenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.COC1=C(C=NNC(N)=N)C=C(Br)C=C1[N+]([O-])=O WSNKYMRJFVHMND-UHFFFAOYSA-N 0.000 description 1
- TVSCNSTYGZWZMS-UHFFFAOYSA-N 2-[(diaminomethylidenehydrazinylidene)methyl]benzenesulfonic acid;hydrochloride Chemical compound Cl.NC(=N)NN=CC1=CC=CC=C1S(O)(=O)=O TVSCNSTYGZWZMS-UHFFFAOYSA-N 0.000 description 1
- FZGICYVEFPCIJR-UHFFFAOYSA-N CC(O)=O.COc1cc(O)c(C=NNC(N)=N)c(OC)c1 Chemical compound CC(O)=O.COc1cc(O)c(C=NNC(N)=N)c(OC)c1 FZGICYVEFPCIJR-UHFFFAOYSA-N 0.000 description 1
- NKTPTBRFGPRMNV-UHFFFAOYSA-N CC(O)=O.COc1ccc(C=NNC(N)=N)c(O)c1 Chemical compound CC(O)=O.COc1ccc(C=NNC(N)=N)c(O)c1 NKTPTBRFGPRMNV-UHFFFAOYSA-N 0.000 description 1
- WXUSRYRMPVIFSJ-UHFFFAOYSA-N Cl.CC1=CC(O)=C(C=NNC(N)=N)C=C1[N+]([O-])=O Chemical compound Cl.CC1=CC(O)=C(C=NNC(N)=N)C=C1[N+]([O-])=O WXUSRYRMPVIFSJ-UHFFFAOYSA-N 0.000 description 1
- WYIQRGNHAFDUJB-UHFFFAOYSA-N Cl.COC1=CC([N+]([O-])=O)=CC(C=NNC(N)=N)=C1O Chemical compound Cl.COC1=CC([N+]([O-])=O)=CC(C=NNC(N)=N)=C1O WYIQRGNHAFDUJB-UHFFFAOYSA-N 0.000 description 1
- GOKZZNWSZZAMPR-UHFFFAOYSA-N Cl.COC1=CC=C([N+]([O-])=O)C(C=NNC(N)=N)=C1[N+]([O-])=O Chemical compound Cl.COC1=CC=C([N+]([O-])=O)C(C=NNC(N)=N)=C1[N+]([O-])=O GOKZZNWSZZAMPR-UHFFFAOYSA-N 0.000 description 1
- NNSCTDFNTPTKDH-UHFFFAOYSA-N Cl.NC(=N)NN=CC1=C(Cl)C=CC([N+]([O-])=O)=C1[N+]([O-])=O Chemical compound Cl.NC(=N)NN=CC1=C(Cl)C=CC([N+]([O-])=O)=C1[N+]([O-])=O NNSCTDFNTPTKDH-UHFFFAOYSA-N 0.000 description 1
- JVNDWFBBXAJJMP-UHFFFAOYSA-N acetic acid 2-[(3,5-dinitrophenyl)methylideneamino]guanidine dihydrate Chemical compound O.O.CC(O)=O.NC(=N)NN=Cc1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O JVNDWFBBXAJJMP-UHFFFAOYSA-N 0.000 description 1
- HXTUKJJBEGTJPF-UHFFFAOYSA-N acetic acid;2-[(2,3-difluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=CC(F)=C1F HXTUKJJBEGTJPF-UHFFFAOYSA-N 0.000 description 1
- PQYJMHHAGLHLAW-UHFFFAOYSA-N acetic acid;2-[(2,3-dimethoxy-5,6-dinitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC([N+]([O-])=O)=C([N+]([O-])=O)C(C=NN=C(N)N)=C1OC PQYJMHHAGLHLAW-UHFFFAOYSA-N 0.000 description 1
- XUHYROIDEFAERS-UHFFFAOYSA-N acetic acid;2-[(2,3-dimethoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC([N+]([O-])=O)=CC(C=NN=C(N)N)=C1OC XUHYROIDEFAERS-UHFFFAOYSA-N 0.000 description 1
- MHJUAHCGSDHUCN-UHFFFAOYSA-N acetic acid;2-[(2,4-dimethoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC(OC)=C([N+]([O-])=O)C=C1C=NN=C(N)N MHJUAHCGSDHUCN-UHFFFAOYSA-N 0.000 description 1
- AYGPUXPCAFIMIG-UHFFFAOYSA-N acetic acid;2-[(2-bromo-4-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C([N+]([O-])=O)C=C1Br AYGPUXPCAFIMIG-UHFFFAOYSA-N 0.000 description 1
- QDGQJMCEAHTZKE-UHFFFAOYSA-N acetic acid;2-[(2-bromo-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC([N+]([O-])=O)=CC=C1Br QDGQJMCEAHTZKE-UHFFFAOYSA-N 0.000 description 1
- YQHLHWOPFVZJAT-UHFFFAOYSA-N acetic acid;2-[(2-fluoro-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC([N+]([O-])=O)=CC=C1F YQHLHWOPFVZJAT-UHFFFAOYSA-N 0.000 description 1
- GWMVDBKCYKUESY-UHFFFAOYSA-N acetic acid;2-[(2-iodophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=CC=C1I GWMVDBKCYKUESY-UHFFFAOYSA-N 0.000 description 1
- YKUUEEAVWUIRHZ-UHFFFAOYSA-N acetic acid;2-[(3,4-difluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C(F)=C1 YKUUEEAVWUIRHZ-UHFFFAOYSA-N 0.000 description 1
- BIBSTXHVXAUVSG-UHFFFAOYSA-N acetic acid;2-[(3,5-dichloro-2-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC(Cl)=CC(Cl)=C1[N+]([O-])=O BIBSTXHVXAUVSG-UHFFFAOYSA-N 0.000 description 1
- BGMARYPSDDQNRG-UHFFFAOYSA-N acetic acid;2-[(3,5-dichloro-4-methoxyphenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=C(Cl)C=C(C=NN=C(N)N)C=C1Cl BGMARYPSDDQNRG-UHFFFAOYSA-N 0.000 description 1
- MTEYXIZIIAMIRC-UHFFFAOYSA-N acetic acid;2-[(3,6-dichloro-2-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=C(Cl)C=CC(Cl)=C1[N+]([O-])=O MTEYXIZIIAMIRC-UHFFFAOYSA-N 0.000 description 1
- LDDRALBTDIPTAT-UHFFFAOYSA-N acetic acid;2-[(3-bromo-4-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C(Br)=C1 LDDRALBTDIPTAT-UHFFFAOYSA-N 0.000 description 1
- WBGNGAZJSTVCGF-UHFFFAOYSA-N acetic acid;2-[(3-bromo-4-methoxy-5-methylphenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=C(C)C=C(C=NN=C(N)N)C=C1Br WBGNGAZJSTVCGF-UHFFFAOYSA-N 0.000 description 1
- WXKJDNXETFDYLD-UHFFFAOYSA-N acetic acid;2-[(3-chloro-4-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C(Cl)=C1 WXKJDNXETFDYLD-UHFFFAOYSA-N 0.000 description 1
- QXHRYVVURDNEBE-UHFFFAOYSA-N acetic acid;2-[(3-hydroxy-4-methyl-2-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.CC1=CC=C(C=NN=C(N)N)C([N+]([O-])=O)=C1O QXHRYVVURDNEBE-UHFFFAOYSA-N 0.000 description 1
- RHSRSSZJWYTEOM-UHFFFAOYSA-N acetic acid;2-[(4-bromo-2-fluoro-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC([N+]([O-])=O)=C(Br)C=C1F RHSRSSZJWYTEOM-UHFFFAOYSA-N 0.000 description 1
- UUIQJIHFDPBYAR-UHFFFAOYSA-N acetic acid;2-[(4-bromo-2-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(Br)C=C1F UUIQJIHFDPBYAR-UHFFFAOYSA-N 0.000 description 1
- ULXODIFGXWJDAE-UHFFFAOYSA-N acetic acid;2-[(4-bromo-3-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(Br)C([N+]([O-])=O)=C1 ULXODIFGXWJDAE-UHFFFAOYSA-N 0.000 description 1
- WAQPKHNUTDJSKY-UHFFFAOYSA-N acetic acid;2-[(4-chloro-2-methoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC(Cl)=C([N+]([O-])=O)C=C1C=NN=C(N)N WAQPKHNUTDJSKY-UHFFFAOYSA-N 0.000 description 1
- MOPSPQWIEOJJIG-UHFFFAOYSA-N acetic acid;2-[(4-chloro-3-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(Cl)C(F)=C1 MOPSPQWIEOJJIG-UHFFFAOYSA-N 0.000 description 1
- IMFGNFNOWZDLKV-UHFFFAOYSA-N acetic acid;2-[(4-fluoro-3-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C([N+]([O-])=O)=C1 IMFGNFNOWZDLKV-UHFFFAOYSA-N 0.000 description 1
- OYRPZHBFIZLANB-UHFFFAOYSA-N acetic acid;2-[(4-methoxy-3-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC=C(C=NN=C(N)N)C=C1[N+]([O-])=O OYRPZHBFIZLANB-UHFFFAOYSA-N 0.000 description 1
- GHHRHXOHRDBWHA-UHFFFAOYSA-N acetic acid;2-[(5-bromo-2,4-dimethoxyphenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC(OC)=C(C=NN=C(N)N)C=C1Br GHHRHXOHRDBWHA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0019357.3 | 2000-07-08 | ||
| GB0019357A GB0019357D0 (en) | 2000-08-07 | 2000-08-07 | Novel phenyl guanidines |
| PCT/GB2001/003534 WO2002011715A2 (en) | 2000-08-07 | 2001-08-07 | The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011148414A Division JP5683396B2 (ja) | 2000-08-07 | 2011-07-04 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004505912A JP2004505912A (ja) | 2004-02-26 |
| JP2004505912A5 true JP2004505912A5 (enExample) | 2007-08-30 |
| JP5654190B2 JP5654190B2 (ja) | 2015-01-14 |
Family
ID=9897134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002517052A Expired - Fee Related JP5654190B2 (ja) | 2000-08-07 | 2001-08-07 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
| JP2011148414A Expired - Fee Related JP5683396B2 (ja) | 2000-08-07 | 2011-07-04 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011148414A Expired - Fee Related JP5683396B2 (ja) | 2000-08-07 | 2011-07-04 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US20040024060A1 (enExample) |
| EP (1) | EP1313461A2 (enExample) |
| JP (2) | JP5654190B2 (enExample) |
| KR (1) | KR100929363B1 (enExample) |
| AU (1) | AU2001276522A1 (enExample) |
| BR (1) | BR0113053A (enExample) |
| CA (1) | CA2417098A1 (enExample) |
| GB (1) | GB0019357D0 (enExample) |
| IL (2) | IL154272A0 (enExample) |
| MX (1) | MXPA03001072A (enExample) |
| WO (1) | WO2002011715A2 (enExample) |
| ZA (1) | ZA200300829B (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001269092A1 (en) * | 2000-06-27 | 2002-01-08 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
| GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| GB0108631D0 (en) * | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
| GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| EP1441712A4 (en) * | 2001-10-12 | 2007-05-30 | Cornell Res Foundation Inc | REVERSAL OR PREVENT PREMATURE AGING OF VESSELS |
| US20030229025A1 (en) * | 2002-02-25 | 2003-12-11 | Chiron Corporation | Intranasal administration of MC4-R agonists |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
| WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
| CA2619770A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| US20080255084A1 (en) | 2005-10-21 | 2008-10-16 | Randy Lee Webb | Combination of Organic Compounds |
| EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
| US8158791B2 (en) | 2005-11-10 | 2012-04-17 | Msd K.K. | Aza-substituted spiro derivatives |
| ATE508111T1 (de) | 2006-06-09 | 2011-05-15 | Action Pharma As | Phenylpyrrolaminoguanidinderivate |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| GB0623381D0 (en) * | 2006-11-23 | 2007-01-03 | Acure Pharma Ab | Use of a compound as VEGF inhibitor |
| GB0624987D0 (en) | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| TWI618544B (zh) | 2006-12-26 | 2018-03-21 | 藍瑟斯醫學影像公司 | 使心臟神經分布顯像之配位體 |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8442179B2 (en) * | 2007-10-19 | 2013-05-14 | The Boeing Company | Method and apparatus for tagging and identifying a target |
| WO2009111037A2 (en) * | 2008-03-04 | 2009-09-11 | Indigene Pharmaceuticals Inc. | Compositions and methods for treating nos-associated diseases |
| US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
| US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| CA2727914A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diaryl ketoxime derivative technical field |
| AU2009277736A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| JP5607719B2 (ja) * | 2009-03-24 | 2014-10-15 | アナマル アクチボラゲット | 代謝プロファイル |
| NZ598124A (en) * | 2009-07-31 | 2014-01-31 | Anamar Ab | Compounds for treatment of inflammation |
| MX348958B (es) | 2010-02-08 | 2017-07-04 | Lantheus Medical Imaging Inc | Métodos y aparatos para sintetizar agentes formadores de imagen e intermedios de estos. |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| JP5992399B2 (ja) | 2010-05-11 | 2016-09-14 | ランセウス メディカル イメージング， インコーポレイテッド | 造影剤の合成および使用のための組成物、方法およびシステム |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| PH12013501686A1 (en) | 2011-02-25 | 2017-10-25 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| KR102527562B1 (ko) * | 2011-09-09 | 2023-05-03 | 랜티우스 메디컬 이메징, 인크. | 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템 |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2749657T3 (es) | 2014-07-02 | 2020-03-23 | Inflectis Bioscience | Derivados de O-alquil-bencilidenguanidina y su uso terapéutico para el tratamiento de trastornos asociados a una acumulación de proteínas mal plegadas |
| PT3164123T (pt) * | 2014-07-02 | 2020-07-24 | Inflectis Bioscience | Novas utilizações terapêuticas de derivados de benzilidenoguanidina para o tratamento de proteopatias |
| RU2021109549A (ru) | 2014-08-29 | 2021-05-13 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ |
| MX382385B (es) * | 2015-04-08 | 2025-03-12 | Res & Innovation Uk | Métodos para seleccionar inhibidores selectivos de fosfatasa e inhibidores no selectivos de fosfatasa. |
| AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US20180230105A1 (en) | 2017-01-13 | 2018-08-16 | Regents Of The University Of Minnesota | Therapeutic compounds |
| CN108066763A (zh) * | 2017-12-21 | 2018-05-25 | 陈敏 | Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用 |
| JP2021529729A (ja) * | 2018-05-09 | 2021-11-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｉ型ｉｆｎ依存性病態を処置するためのグアナベンズ又はその誘導体の使用 |
| MX2021005904A (es) | 2018-11-20 | 2021-09-08 | Tes Pharma S R L | Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa. |
| EP3773558B1 (en) | 2019-05-10 | 2022-06-15 | SynAct Pharma ApS | Combination treatment of arthritic disease |
| ES3045575T3 (en) | 2021-06-21 | 2025-11-28 | Synact Pharma Aps | Phenyl pyrrole aminoguanidine salts and formulations |
| US20240293343A1 (en) | 2023-02-13 | 2024-09-05 | Inflectis Bioscience | Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2584784A (en) * | 1949-05-21 | 1952-02-05 | Du Pont | Salts of 1-salicylalaminoguanidine |
| GB892117A (en) | 1958-06-20 | 1962-03-21 | May & Baker Ltd | Phenanthridine salts and their preparation |
| GB923398A (en) | 1960-08-09 | 1963-04-10 | Vismara Francesco Spa | Diphenyl mono-and bis-formyl guanylhydrazones |
| DE1165013B (de) | 1960-08-09 | 1964-03-12 | Vismara Francesco Spa | Verfahren zur Herstellung von Guanylhydrazonen |
| GB1019120A (en) | 1964-03-18 | 1966-02-02 | Shell Int Research | Novel hydrazine compounds and compositions containing them |
| GB1204631A (en) | 1967-10-12 | 1970-09-09 | Shell Int Research | Pharmacologically active benzylideneamino guanidines and their use |
| GB1223491A (en) | 1967-10-13 | 1971-02-24 | American Home Prod | Guanidines |
| CH500953A (de) | 1967-11-13 | 1970-12-31 | Sandoz Ag | Verfahren zur Herstellung von neuen N-Benzyliden-N'-amidinohydrazinen |
| US3591636A (en) * | 1968-09-16 | 1971-07-06 | Sandoz Ag | Substituted benzylideneamino guanidines |
| GB1223493A (en) | 1968-10-11 | 1971-02-24 | American Home Prod | Guanidines |
| US3592852A (en) * | 1968-12-16 | 1971-07-13 | Sandoz Ag | Substituted benzylideneamino guanidine |
| DE2015321A1 (en) | 1969-04-04 | 1970-10-08 | Sandoz Ag, Basel (Schweiz) | Novel guanidine derivs |
| FR2036989A1 (en) * | 1969-04-28 | 1970-12-31 | Anvar | Amidino hydrazone antivirals |
| US3541218A (en) * | 1969-06-18 | 1970-11-17 | Lilly Co Eli | Omicron-fluorobenzylaminoguanidine for diabetes |
| US3592935A (en) * | 1969-12-11 | 1971-07-13 | Sandoz Ag | Substituted benzylidene hydrazines as anti-inflammatory agents |
| US3982020A (en) * | 1970-03-17 | 1976-09-21 | Sandoz, Inc. | Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation |
| US3975533A (en) * | 1970-04-29 | 1976-08-17 | Shell Oil Company | Therapeutic agents |
| US4060640A (en) * | 1970-04-29 | 1977-11-29 | Shell Oil Company | Therapeutic agents |
| JPS4842969B1 (enExample) | 1970-12-30 | 1973-12-15 | ||
| BE791536A (fr) * | 1971-11-19 | 1973-05-17 | Merck & Co Inc | Nouvelles 1,3-diamino guanidines substituees |
| US3896232A (en) * | 1973-01-11 | 1975-07-22 | Sandoz Ag | Substituted benzylidene hydrazines as anti-migraine syndrome agents |
| US3941825A (en) * | 1973-07-27 | 1976-03-02 | American Cyanamid Company | Substituted aminobenzylideneamino guanidine compounds |
| US4006249A (en) * | 1975-08-06 | 1977-02-01 | American Home Products Corporation | Systemic treatment of psoriasis |
| US4006250A (en) * | 1975-08-25 | 1977-02-01 | American Home Products Corporation | Systemic treatment of psoriasis |
| FR2324294A1 (fr) | 1975-09-22 | 1977-04-15 | Roussel Uclaf | Nouveau medicament hypotenseur a action retardee, ainsi que le procede de preparation de ce nouveau medicament |
| GB1550401A (en) * | 1976-01-07 | 1979-08-15 | Hexachimie | Hydrazine derivatives their preparation and their use |
| DE2620369C3 (de) * | 1976-05-08 | 1979-01-04 | Bayer Ag, 5090 Leverkusen | Verfahren zur Wiedergewinnung von (l-S)-2-Oxo-bornansulfonat-(10) |
| US4312886A (en) * | 1978-07-20 | 1982-01-26 | American Home Products Corporation | Prevention of gastric ulcers and depression of gastric secretion by administration of guanabenz |
| JPS5562017A (en) | 1978-11-01 | 1980-05-10 | Teijin Ltd | Anti-inflammatory agent comprising guanidine derivative |
| US5958933A (en) * | 1982-11-23 | 1999-09-28 | Naftchi; N. Eric | Neurologically active compounds and compounds with multiple activities |
| US4983604A (en) | 1987-11-13 | 1991-01-08 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
| ZA853488B (en) | 1984-05-10 | 1986-12-30 | American Home Prod | Transdermal dosage form |
| DE3428342A1 (de) * | 1984-08-01 | 1986-02-13 | Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim | Futtermittelzusatz zur verbesserung des wachstums bei landwirtschaftlichen nutztieren |
| US6413962B1 (en) * | 1988-05-02 | 2002-07-02 | N. Eric Naftchi | Guanidino compounds effective as anesthetics |
| DE69130216T2 (de) | 1990-03-16 | 1999-03-25 | The Beth Israel Hospital Association, Boston, Mass. | Verwendung von spiperon als immunsuppressivum und antiinflammatorisches mittel |
| CA2104873C (en) | 1991-02-26 | 2000-05-23 | James N. Campbell | Compositions and methods of treatment of sympathetically maintained pain |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| JPH06510760A (ja) * | 1991-08-27 | 1994-12-01 | ジ・アップジョン・カンパニー | 代謝障害および代謝の治療法 |
| US5696128A (en) | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| WO1995003286A1 (en) * | 1993-07-23 | 1995-02-02 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
| EP0711553A1 (en) | 1994-08-09 | 1996-05-15 | Mario Cagnoni | Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis |
| US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| WO1996018607A1 (en) * | 1994-12-12 | 1996-06-20 | Chugai Seiyaku Kabushiki Kaisha | Aniline derivative having the effect of inhibiting nitrogen monoxide synthase |
| US5602277A (en) | 1995-03-30 | 1997-02-11 | Biocryst Pharmaceuticals, Inc. | Substituted benzene derivatives useful as neuraminidase inhibitors |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| SE9604348D0 (sv) * | 1996-11-26 | 1996-11-26 | Wapharm Ab | Användning av hydroxyguanidiner |
| WO1999021571A1 (en) | 1997-10-27 | 1999-05-06 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
| AU3166299A (en) | 1998-04-09 | 1999-11-01 | Eisai Co. Ltd. | Arginine peptide analogs useful as fibroblast growth factor antagonists |
| US6127381A (en) | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| WO2000009115A1 (en) | 1998-08-14 | 2000-02-24 | Smithkline Beecham Corporation | Grp receptor ligands |
| GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
| US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
| WO2001005401A1 (en) | 1999-07-16 | 2001-01-25 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
| AU6528400A (en) | 1999-08-23 | 2001-03-19 | David M. Ockert | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
| AU7802700A (en) * | 1999-10-06 | 2001-05-10 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
| GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| GB0019359D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| GB0108631D0 (en) | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
| GB0119172D0 (en) * | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| US7060711B2 (en) | 2001-10-25 | 2006-06-13 | Biofrontera Bioscience Gmbh | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| GB0622826D0 (en) * | 2006-11-15 | 2006-12-27 | Acurepharma Ab | Novel amides acting on the adenosine receptors |
| GB0624987D0 (en) * | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
-
2000
- 2000-08-07 GB GB0019357A patent/GB0019357D0/en not_active Ceased
-
2001
- 2001-08-07 MX MXPA03001072A patent/MXPA03001072A/es active IP Right Grant
- 2001-08-07 AU AU2001276522A patent/AU2001276522A1/en not_active Abandoned
- 2001-08-07 EP EP20010954176 patent/EP1313461A2/en not_active Withdrawn
- 2001-08-07 CA CA 2417098 patent/CA2417098A1/en not_active Abandoned
- 2001-08-07 US US10/343,325 patent/US20040024060A1/en not_active Abandoned
- 2001-08-07 BR BR0113053A patent/BR0113053A/pt not_active Application Discontinuation
- 2001-08-07 JP JP2002517052A patent/JP5654190B2/ja not_active Expired - Fee Related
- 2001-08-07 KR KR20037001846A patent/KR100929363B1/ko not_active Expired - Fee Related
- 2001-08-07 IL IL15427201A patent/IL154272A0/xx unknown
- 2001-08-07 WO PCT/GB2001/003534 patent/WO2002011715A2/en not_active Ceased
-
2003
- 2003-01-30 ZA ZA200300829A patent/ZA200300829B/xx unknown
- 2003-02-03 IL IL15427203A patent/IL154272A/en not_active IP Right Cessation
-
2006
- 2006-12-15 US US11/639,190 patent/US8148429B2/en not_active Expired - Fee Related
-
2007
- 2007-05-16 US US11/798,669 patent/US20070231267A1/en not_active Abandoned
-
2010
- 2010-09-28 US US12/892,402 patent/US8309609B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 JP JP2011148414A patent/JP5683396B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-21 US US13/426,096 patent/US8410174B2/en not_active Expired - Fee Related
-
2013
- 2013-03-14 US US13/803,555 patent/US9227927B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004505912A5 (enExample) | ||
| JP2004505947A5 (enExample) | ||
| EP1797878A3 (en) | Benzothiazole derivatives | |
| TR200001795T2 (tr) | 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı. | |
| JP2005516967A5 (enExample) | ||
| CA2349142A1 (en) | Compositions and methods for stimulating gastrointestinal motility | |
| BR0213358A (pt) | Uso de flibanserina | |
| DK1404331T3 (da) | Sustained release-formuleringer af oxymorphon | |
| JP2005525345A5 (enExample) | ||
| JP2010523477A5 (enExample) | ||
| JP2004500426A5 (enExample) | ||
| JP2007526238A5 (enExample) | ||
| JP2002535370A5 (enExample) | ||
| RU2007106930A (ru) | Производные хиназолина | |
| JPH10147529A5 (enExample) | ||
| RU2004136999A (ru) | Способы лечения болевых расстройств желудочно-кишечной и мочеполовой систем, использующие венлфаксин и его производные | |
| EP1431286A3 (en) | Prodigiosin derivatives for treating cancer or viral diseases | |
| CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
| MY133512A (en) | Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | |
| CA2373634A1 (en) | Isophosphoramide mustard analogs and use thereof | |
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| JP2006510659A5 (enExample) | ||
| AU690661B2 (en) | New use of quinoline-3-carboxamide compounds | |
| AU2003232805A8 (en) | Pharmaceutical active substance combination and the use thereof | |
| JP2003505513A5 (enExample) |